Which cardiometabolic drugs go off patent, and when?
13 blockbuster cardiometabolic drugs with about $129.8B in 2025 worldwide sales lose US exclusivity between 2025 and 2037, led by Mounjaro (Eli Lilly, $23.0B). 4 lose it in 2025 or 2026; the biggest single year is 2036, with $36.5B.
2025 worldwide sales of each drug, placed in the year its first US generic or biosimilar can launch. Select a year for every drug going off patent that year.
| Drug | Company | US LOE | 2025 sales | Date basis | US copies | Medicare price |
|---|---|---|---|---|---|---|
| Entresto | Novartis | 2025 | $7.7B | Generics launched | Copies on the US market | 2026 · −53% |
| Xarelto | Bayer / Johnson & Johnson | 2025 | ≈$5.3B | Generics launched | Copies on the US market | 2026 · −62% |
| Farxiga | AstraZeneca | 2026 | $8.4B | Generics launched | Copies on the US market | 2026 · −68% |
| Januvia | Merck | 2026 | $2.5B | Generics launched | Copies on the US market | 2026 · −79% |
| Trulicity | Eli Lilly | 2027 | $4.3B | Company guidance | Early development | 2028 · pending |
| Eliquis | Bristol Myers Squibb / Pfizer | 2028 | $14.4B | Settlement / court date | Approved, waiting to launch | 2026 · −56% |
| Jardiance | Boehringer Ingelheim / Eli Lilly | 2029 | ≈$9.9B | Company guidance | Filed with the FDA | 2026 · −66% |
| Repatha | Amgen | 2029 | $3.0B | Patent-expiry estimate | No US filing found | – |
| Vyndaqel | Pfizer | 2031 | $6.4B | Settlement / court date | Filed with the FDA | – |
| Ozempic | Novo Nordisk | 2032 | ≈$19.3B | Company guidance | Filed with the FDA | 2027 · −71% |
| Wegovy | Novo Nordisk | 2032 | ≈$12.0B | Company guidance | Filed with the FDA | 2027 · −71% |
| Mounjaro | Eli Lilly | 2036 | $23.0B | Company guidance | Filed with the FDA | – |
| Zepbound | Eli Lilly | 2036 | $13.5B | Company guidance | Filed with the FDA | – |
Sorted by the year US exclusivity ends. Each drug's page has the sources.
| Company | Drugs | 2025 revenue from them | Share of company |
|---|---|---|---|
| Eli Lilly | Trulicity, Jardiance, Mounjaro and Zepbound | $44.2B | 68% |
| Novo Nordisk | Ozempic and Wegovy | ≈$31.3B | 67% |
| Bristol Myers Squibb | Eliquis | $14.4B | 30% |
| Pfizer | Eliquis and Vyndaqel | $14.3B | 23% |
| Boehringer Ingelheim | Jardiance | ≈$9.9B | 32% |
| AstraZeneca | Farxiga | $8.4B | 14% |
| Novartis | Entresto | $7.7B | 14% |
| Amgen | Repatha | $3.0B | 8.2% |
| Bayer | Xarelto | ≈$2.6B | 5.1% |
| Johnson & Johnson | Xarelto | $2.6B | 2.8% |
For shared drugs, each company is credited with the revenue it reports, so nothing is counted twice. Share is of the company's total 2025 revenue.
Entresto (2026, −53%), Xarelto (2026, −62%), Farxiga (2026, −68%), Januvia (2026, −79%), Trulicity (2028, price pending), Eliquis (2026, −56%), Jardiance (2026, −66%), Ozempic (2027, −71%) and Wegovy (2027, −71%) were selected for Medicare price negotiation. See every negotiated Medicare price →